| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
3 companies
Nussbaum Ran is a Director at URGN with holdings across 3 companies. Recent SEC Form 4 filings include 9 buys and 0 sells.
Estimated insider holdings value: $56.8M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | LBRX Lb Pharmaceuticals Inc | Director | Buy | 1,000,000 | $15.00 | $15,000,000.00 | +242.9% | +20.4% | - | |
| Nov 17, 2020 | KROS Keros Therapeutics, Inc. | Director, 10% Owner | Buy | 60,000 | $50.00 | $3,000,000.00 | +1.3% | - | - | |
| Apr 13, 2020 | KROS Keros Therapeutics, Inc. | Director, 10% Owner | Buy | 437,499 | $16.00 | $6,999,984.00 | +10.2% | - | - |